Innovative Detection Technology Breath Diagnostics has developed a patented, non-invasive breath analysis technology capable of detecting lung cancer with parts per billion accuracy, presenting a significant opportunity to market advanced diagnostic tools to healthcare providers focused on early detection.

Growing Market Potential With an estimated revenue between 10 and 25 million dollars and a global shift towards early, non-invasive disease detection, the company is well-positioned to expand its sales efforts into hospitals, clinics, and research institutions seeking innovative diagnostic solutions.

Key Leadership Appointment The recent appointment of Aaron Roebuck as President signals strategic growth and increased focus on business development, making now an opportune time for outreach to establish partnerships or secure new clients in the healthcare industry.

Expanding Industry Presence Breath Diagnostics is operating in a competitive space alongside companies like Owlstone Medical, which indicates potential for collaboration, strategic partnerships, or customer cross-sell opportunities with entities already investing in breath analysis technologies.

Focused Research & Development Having studied over 800 patients, the company has a solid foundation of clinical research that can be leveraged to demonstrate efficacy and facilitate sales conversions, especially to research hospitals and academic institutions prioritizing innovative diagnostic technologies.